PeptideStack
5.2kquestions
20kanswers
220users

Why would PeptideMeter report 97.9% where the supplier certificate says something higher?

Asked 11 Apr 2024Modified 23 months agoViewed 19k times
31

Concretely: PeptideMeter · 97.9%.

I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.

I want to know whether this is recoverable or whether the honest answer is to write it off.

Should I be treating this as a failure or as noise?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
shareeditfollowflag
KL
askedkirsi_lahtinen45k3811 Apr 2024
8Small correction: the units in the third paragraph should be micrograms, not milligrams. – Dr_Signe_Baldursdottir 8 months ago
Do you have a reference for the last claim? Not disputing it, just want to read it. – mz_4113 10 months ago
add a comment

5 Answers

Accepted answer first, then by votes
57

Accepted answer

To be exact about it, read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Reconciling gross mass to label claim

ComponentTypical shareCounted in purity?Counted in content?
Target peptide88–94 %Yes, as main peakYes
Related impurities1–3 %Yes, as other peaksNo
Counter-ion (TFA or acetate)2–8 %NoNo
Residual water2–6 %NoNo
Bulking agent, if present0–40 %NoNo

Specifically, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
OF
answered · acceptedorla_ferriter47k3816 Apr 2024
I have seen exactly this failure mode twice and both times it was the diluent. – h_pergande 6 months ago
2The distinction between purity and content cannot be repeated often enough here. – Dr_Malik_Osei 8 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
23

It helps to be literal here: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

In practice, tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
SD
answeredsunniva_dahl11k281 Jul 2024
21

In practice, the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Put another way, the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
ID
answeredimani_dube19k2827 Apr 2024
15

Reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
TO
answeredt_oyelaran41k3823 Jul 2024
5Confirming from the other direction: I did the wrong thing and got exactly the predicted outcome. – anja_hellstrom 39 days ago
4Is there a reason to prefer the second method over the first, other than cost? – gradient_slope 10 months ago
add a comment
11

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 17 Aug 2024 by Dr_Colm_Fitzhenry — tightened the wording; no substantive change

shareimprove this answerflag
DF
answeredDr_Colm_Fitzhenry85k2483 Aug 2024
2Adding for future readers: the certificate should carry the lot number, not just a batch code. – triple_agonist_q 4 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.